
Centogene and Anylam launch clinical programme
ATTRv is an autosomal dominant condition caused by a pathogenic variant in the TTR gene coding for transthyretin (prealbumin)....

Vifor Pharma inks $340m deal with Angion Biomedica Inc.
Under the deal, Zurich-based Vifor Pharma will pay $30m upfront, make a $30m equity investment in Angion Biomedica and hold out the prospect of...

BI initiates Phase II testing of COVID-19 drug
A new potential weapon against severe complications such as ARDS caused by the new coronavirus SARS-CoV-2 have been advanced by Boehringer Ingelheim...

COVID-19 test gives results within minutes
The method is published on MedRxiv, where the researchers headed by Professor Tim Dafforn from the University of Birmingham also...

Servier and MiNA Therapeutics sign €220m deal
Under the agreement, MiNA Therapeutics will use its small activating RNA platform (saRNA) to identify candicate saRNAs that can restore normal cell...

Germany first EU country to launch COVID-19 therapy offensive?
"Besides protection by masks, social distancing etc, rapid diagnostic testing, and COVID-19 vaccines, we are now establishing a fourth pillar of...